OBJECTIVE: The aim of this study was to evaluate characteristics of patients with heart failure (HF) with preserved ejection fraction (HFPEF) and to assess prognostic predictors in 2-year follow-up. METHODS: We included prospectively 109 patients admitted to the internal department for HF, grouped into HFPEF (EF>40 %, n = 63) and HF with reduced EF (HFREF) (EF ≤ 40 %, n = 46). Preserved right ventricular systolic function (PRV) was defi ned as the peak systolic tricuspid annular velocity (S') > 10.8 cm/s. RESULTS: HFPEF and HFREF patients had non-signifi cantly different 2-year all-cause and CV mortality (28.6 % vs 37.0 %, 17.5 % vs 21.7 %). Patients with HFPEF and PRV vs dysfunctional RV had a better survival (76.6 % vs 56.3 %, p=0.045). In HFPEF, the patients who survived had a trend to better S' (13.6 ± 3.1 cm/s vs 11.9 ± 3.4 cm/s, p=0.055), shorter QTc (427 ± 42ms vs 454 ± 42ms, p = 0.058), and all-cause mortality was lowered only by anticoagulants (12.0 % vs 39.5 %, p = 0.02). QTc interval and PRV emerged as predictors of all-cause mortality (HR 1.7 per 40 ms change, 95 % CI 1.1-2.6, p = 0.02, HR 0.38, 95 % CI 0.15-0.93, p = 0.03). CONCLUSIONS: In HFPEF, we observed a trend to lower all-cause and CV mortality compared to HFREF and anticoagulants were the only therapy that signifi cantly lowered mortality. PRV and QTc interval emerged as independent predictors of survival (Tab. 6, Fig. 2, Ref. 26) . Text in PDF www.elis.sk.
Introduction
Heart failure (HF) with preserved left ventricular ejection fraction (HFPEF) is a common form of HF in the population (1) . HFPEF comprises almost 50 % of HF patients, depending on defi nition (2) (3) (4) . T he prognosis is generally poor, and it remains unclear whether it is better or worse compared to heart failure with reduced left ventricular ejection fraction (HFREF) (2, (5) (6) (7) (8) . The immediate post-discharge prognosis is better in HFPEF but longterm mortality is similar (2, 9) . Annual mortality in HFPEF ranges from 10-30 %, with around 60 % of cardiovascular (CV) deaths, which comprises mostly sudden death and HF death depending on the clinical or epidemiological type of study (2, 9, 10) . Even though many studies were performed with the focus on prognosis improvement, no effective treatment was found (11) .
We set this study to determine the complex characteristics of HFPEF, its prognosis and the possible predictors of survival in patients routinely treated in the internal department.
Methods
We prospectively enrolled 109 consecutive patients with HF admitted to the Department of Internal Medicine within a one-year period (2010) (2011) . Patients with known advanced malignant tumors, whose expected survival was less than one year, were excluded. The diagnosis of HF was made according to the guidelines of the European Society of Cardiology (11) . Patients were divided into the two groups according to the left ventricular ejection fraction (LVEF), as assessed by echocardiography: HFPEF with LVEF > 40 % (n=63) and HFREF with LVEF ≤40 % (n = 46) (2, 9) .
The vital status of the patients was ascertained at regular visits, by general practitioners, and from hospital records as well as by family members. All-cause mortality was defi ned as death from any cause and CV mortality as death from any documented CV cause. Cumulative CV endpoint was defi ned as all-cause mortality or myocardial infarction or stroke. Patients were followed-up for 24 months and visits were scheduled every 6 months after discharge. All echocardiographic measurements were performed according to the American Society of Echocardiography (12) . LV diastolic dysfunction was classifi ed into the three degrees (13) . We ca lculated the LVEF according to the Simpson's biplane method. Right ventricular (RV) systolic function was evaluated by the peak systolic velocity of the lateral tricuspid annulus (S') in tissue Doppler imaging. Normal RV systolic function was defi ned as the S' value more than 10.8 cm/s (13, 14) . Pulmonary artery systolic pressure (sPAP) was calculated as the maximal gradient of tricuspid regurgitation + the estimated value of the right atrial systolic pressure. We measured the vena cava size as the maximum diameter of vena cava before merging with the right atrium during expirium. The study was performed according to the Declaration of Helsinki and hospital ethical standards.
Statistical analysis
Categorical data were expressed as frequencies and percentages. Continuous data were expressed as the means and standard deviations and in case of abnormal distribution as the median and interquartile range (IQR). The comparison of categorical variables was performed using the Fisher's exact test. The comparison of continuous variables was performed using T-test and Mann-Whitney non-parametric U-test. Correlations were analyzed with a linear regression analysis and non-parametric Spearman's correlation coeffi cient. The log-rank test was used to determine if survival was signifi cantly different. Hazard ratios (HRs) were calculated using Cox proportional hazards model. We included all examined parameters (demographic data, therapy, echocardiographic, ECG and laboratory parameters) in the hazard ratio models and in statistical analyses of mortality data. Statistical signifi cance was defi ned as p < 0.05. Data were analyzed using the statistical program JMP7, SAS, USA. Table 1 shows basic demographic characteristics on admission. Patients with HFPEF were signifi cantly older with a higher prevalence of female gender and arterial hypertension as compared to HFREF. In the 2-year follow-up, there was a substantial increase in the prevalence of atrial fi brillation in HFPEF and not so prominent increase in HFREF (78 % vs 48 %, p = 0.012). We observed a decrease in the mean systolic blood pressure during fi nal visit compared to the baseline in both HFPEF and HFREF (130 (110-140) vs 130 (120-140), p=NS), respectively. There was non signifi cant difference between both groups in other parameters, i.e. body mass index, prevalence of arterial hypertension, diabetes mellitus and coronary artery disease.
Results
The baseline echocardiographic parameters are in the Table 3 . The heart rate was better controlled in both groups in the fi nal checkup visit (HFPEF vs HFREF: 74 ± 18/min vs 79 ± 18/min, p = NS). The QTc interval after 2 years in HFPEF vs HFREF was 431±44 ms vs 439 ± 48 ms (p = NS). We correlated the echocardiographic parameters of diastolic dysfunction with QTc and QRS. The results are in the Table 4 . In HFPEF and HFREF, we did not fi nd any signifi cant correlation between QRS and E/E´, QRS and E, QRS and the diastolic dysfunction degree.
The laboratory parameters on admission are in Table 5 . After 24 months, the N-terminal-pro-brain natriuretic peptide (NT-proBNP) as well as hemoglobin were non-signifi cantly different in HFPEF vs HFREF (median (IQR) 1335 ng/ml (966-2229) vs 1178 ng/ml (346-2546), p=NS) and (129 g/l±19 vs 133 g/l±18, p=NS). Although the level of NT-proBNP was much lower in both groups compared to the baseline values, the reduction was more prominent in HFREF. Hemoglobin in HFPEF slightly improved compared to initial hospitalization.
The treatment on admission is in Table 6 . In the 2-year followup, the usage of angiotensin converting enzyme (ACE) inhibitors/ angiotensin receptor blockers (ARB) was non-signifi cantly different in HFPEF vs HFREF (76.6 % vs 86.7 %, p=NS). The prescription of mineralocorticoid receptor antagonists (MRA) was non-signifi cantly higher in HFREF vs HFPEF after 2 years (46.7 % vs 40.4 %, p = NS), but it was much higher in the HFPEF group compared to the baseline. In HFPEF, neither medical therapy (diuretics, betablockers, MRA, antiplatelet therapy, statins and ACE inhibitors/ARB) nor ICD/CRT and PCI/CABG infl uenced all-cause mortality. Only patients treated with anticoagulants had a signifi cantly lower all- Compared to the patients with dysfunctional RV, the patients with preserved RV systolic function in HFPEF had a signifi cantly better 2-year survival (76.6 % vs 56.3 %, p = 0.045). The same trend was seen in HFREF and preserved RV function compared to dysfunctional RV (73.7 % vs 55.6 %, p = NS). The patients with HFPEF who died had a strong trend to worse S' (11.9±3.4 cm/s vs 13.6±3.1 cm/s, p=0.055) and prolonged QTc interval (454±42 ms vs 427 ± 42 ms, p = 0.058). The patients with HFREF who died also had a strong trend to worse S' (9.4 ± 3.1 cm/s vs 11.5±3.1 cm/s, p = 0.068) and a lower level of hemoglobin (124.3 ±24 g/l vs 140.4 ± 15 g/l, p = 0.01).
There was a non-signifi cant trend toward a higher prevalence of cumulative CV endpoint in HFREF vs HFPEF (41.3 % vs 31.7 %, p=NS). Re-hospitalizations for HF were non-signifi cantly different in HFPEF and HFREF in the 2-year follow-up (46.0 % vs 50.0 %, p = NS). Using a Cox model after performing the univariate analysis, the QTc interval and the preserved RV systolic function emerged as an independent predictor of all-cause mortality in patients with HFPEF (HR 1.7 per 40 ms change, 95 % CI 1.1-2.6, p =0.02 and HR 0.38 , 95 % CI 0.15 to 0.93, p = 0.03).
Discussion
The present prospective study of 109 patients, focused on HFPEF, with a 24-month follow-up, has three main prognostic fi ndings: 1) the patients with HFPEF had a non-signifi cant trend to better survival and a non-signifi cant trend to lower CV mortality compared to HFREF. 2) Anticoagulants were the only therapy that lowered mortality in HFPEF. 3) The preserved RV systolic function and the QTc interval length merged as the independent predictors of a 2-year survival.
The mortality burden of HFPEF is substantial, ranging from 10 %-30 % annually and long-term mortality in HFPEF vs HFREF is comparable (2, 9, 10) . Although in-hospital mortality is slightly higher in HFREF, 30-day to 1 year mortality is already similar between both groups (2, 6, 9) . We observed a non-signifi cantly better survival in patients with HFPEF vs HFREF in the 2-year follow-up and similar fi ndings were in CV mortality. Similarly to another study, 61 % of the deceased HFPEF patients died from CV causes, which was non-signifi cantly different compared to 65 % in HFREF (15) . After the 2-year follow-up, both HF groups, seem to have almost the same prevalence of comorbidities (arterial hypertension, diabetes mellitus, renal dysfunction), except for the prevalence of atrial fi brillation, which was higher in HF-PEF. The cumulative CV endpoint was non-signifi cantly different in HFREF vs HFPEF and the rate of hospitalization for HF in 2 years was similar, too. A trend to worse prognosis in terms of all above-mentioned parameters (all-cause mortality, CV mortality and cumulative CV endpoint) was found in HFREF.
During the follow-up, we observed that no other treatment than anticoagulants signifi cantly reduced all-cause mortality in HF-PEF (12.0 % vs 39.5 %, p=0.02). We did not distinguish between oral anticoagulants, namely warfarin, and novel anticoagulants (NOAC), because at the beginning of the study, NOAC were not broadly used in our country. The main proportion of the anticoagulation therapy was used due to atrial fi brillation. At the end of the study, there were 78 % vs 48 % patients in HFPEF vs HFREF (p=0.012) with the history of atrial fi brillation. According to these data, the patients in both groups were strongly undertreated. We expect that the risk profi le in our HFPEF patients favors the anticoagulation therapy because of older age, a high prevalence of arterial hypertension and female gender. The low proportion of the treated patients might be partially explained by a higher bleeding risk, while HFPEF patients generally have a poor risk profi le. However, even though there is a more profound mismatch in the prevalence of atrial fi brillation and anticoagulation treatment, we did not observe a signifi cant difference in the prevalence of stroke in both groups. In our study, the patients with HFPEF treated with anticoagulants had signifi cantly lower all-cause mortality vs those not treated. This was not true for HFREF. Shore et al. also observed that HFPEF patients on chronic anticoagulation for a concurrent indication were noted to live longer than those not treated (16) . In this study, the outcome was not linked to anticoagulatio n solely due to atrial fi brillation, because no signifi cant difference in mortality was seen in patients with atrial fi brillation on chronic anticoagulation compared to those not treated (16) . Moreover, no statistically signifi cant difference in the stroke risk was observed between the patients with atrial fi brillation and HFPEF vs HFREF (17) . Thus, the mechanism of a better overall impact of anticoagulation on mortality in HFPEF is unknown.
In accordance with the published studies, we did not fi nd any favorable infl uence of the medications broadly recommended in HFREF on the survival in HFPEF (11) . Signifi cantly lower allcause mortality was noted in patients with HFREF treated with betablockers and ACE inhibitors/ARB compared to those not treated. Interestingly, all-cause mortality was not infl uenced by the MRA treatment in HFREF.
We identifi ed the QTc interval and the RV systolic function as independent predictors of a 2-year survival in HFPEF. We tried to fi nd the link between the QTc and the diastolic function of the LV, based on the assumption that the QTc interval encompasses both the depolarization (systole) and repolarization (diastole) phase. We assume that the repolarization phase is responsible for the infl uence on the predictive value of QTc in HFPEF, hence it shows a worse diastolic dysfunction grade. A few studies found the correlation between QTc and the parameters of diastolic dysfunction (18, 19) . The authors hypothesized that in the narrow QRS, the association between QTc and E′ appeared to be a function of a prolonged repolarization, otherwise in the wide QRS it might be infl uenced by the LV intraventricular and interventricular dyssynchrony (19) . We assessed that the QTc interval in HFPEF correlates signifi cantly with the diastolic dysfunction grade, E velocity and DCT but not with the E/E′ ratio and E′. QTc interval did correlate well with the QRS duration, which could ascertain the above-mentioned hypothesis of Wilcox et al (19) . The most powerful LV diastolic parameter is in our opinion solely the diastolic dysfunction grade, because it merges several echocardiographic parameters. We hypothesize that the infl uence of other parameters, especially the E/E′, might be distorted by the high prevalence of atrial fi brillation and the problematic assessment of the E/E′ ratio under this condition (20) . We think that QTc might be a useful parameter to predict diastolic dysfunction and, according to our data, QTc merges as an independent predictor of a 2-year survival, too.
The second independent predictor of a 2-year survival in HF-PEF was RV systolic function. We observed that preserved RV systolic function was signifi cantly more common in HFPEF and the mean S' was signifi cantly higher in HFPEF vs HFREF. The dysfunctional RV in HFPEF is present in around 1/3 of the patients depending on the study design (21, 22) . Several techniques were used to assess the RV function (13, 22, 23) . We eval uated the RV systolic function by S' because RV volume measurements and tricuspid annular plane systolic excursion (TAPSE) might not be adequately obtainable in all patients, especially in those with decreased echogenicity. The best-known mechanism of RV systolic dysfunction is the passive transmission of LV fi lling pressure, reactive vasoconstriction and remodeling of pulmonary arteries leading to postcapillary pulmonary hypertension. In our study, the RV systolic function seemed to deteriorate with the increasing severity of pulmonary hypertension. This was not the case in HFREF. The correlation between the estimated sPAP and S´ may be negatively infl uenced by the fact that the dysfunctional RV itself might cause the tricuspid gradient to be lower and hence sPAP could not be adequately assessed. Nevertheless, not solely pulmonary hypertension causes the RV dysfunction. Septal dysfunction related to the LV diastolic dysfunction leads to a decrease of the septal role in the RV ejection and thus causes a systolic mechanical dyssynchrony of the RV (24) . There is only limited evidence about the prognostic importance of RV systolic dysfunction in HFPEF (21, 25, 26) . Irrespective of the mechanism of the RV dysfunction and the examination technique, the RV systolic dysfunction is an independent predictor of a poor prognosis in patients with HF in general (13, (23) (24) (25) . We observed in our study that the preserved RV systolic function was an independent predictor of a better survival in HFPEF.
Conclusion
We observed that patients with HFPEF had a non-signifi cant trend to better survival and lower CV mortality compared to HFREF. Anticoagulants were the only therapy that signifi cantly lowered mortality in HFPEF. The preserved RV systolic function and QTc interval length merged as the independent predictors of a 2-year survival.
Learning points
All-cause and CV mortality were non-signifi cantly lower in HFPEF compared to HFREF in a mid-term follow-up.
RV systolic dysfunction assessed by tissue Doppler imaging and QTc interval might predict HFPEF patients with adverse outcome.
Anticoagulants might lower mortality in HFPEF, but the mechanism is unknown.
